Siemens Healthineers signed a global OEM agreement on hemostasis products with Sysmex under which each company will supply the other with their products in the diagnostic field of hemostasis on an OEM basis.
Siemens Healthineers and Sysmex provide, among other things, hemostasis products used in testing for blood clotting disorders, preoperative bleeding risk management, and the monitoring of patients receiving anticoagulant therapy medications.
The OEM agreement positions each company to distribute—globally and individually—under their respective brands the companies’ combined portfolio of hemostasis instruments and reagents, in combination with their own wider portfolios of products and services.1 Going forward, the companies will each individually offer solutions to laboratories worldwide that build on their respective strengths based on their hemostasis product portfolios.
“Siemens Healthineers and Sysmex have built a solid hemostasis partnership for more than 25 years,” says Sharon Bracken, head of diagnostics for Siemens Healthineers. “The time has come to offer one of the world’s most extensive product portfolios achieved through mutual OEM supply to benefit customers and patients worldwide. With the OEM agreement, we will more effectively deliver quality and comprehensive hemostasis testing solutions to laboratories of all sizes across the world.”
In recent years, demand for hemostasis testing has increased and grown more diverse because of a rise in thrombotic diseases stemming from lifestyle diseases, the development of new blood preparations, the use in testing to predict COVID severity, as well as increased demands for standardization, IT connectivity, and quality improvement in testing.
“Making our long-standing partnership with Siemens Healthineers even more sustainable, we remain committed to further enhance the value of hemostasis testing as a global leader,” says Kenji Tachibana, member of the managing board and senior executive officer, senior managing director of Sysmex. “We will individually offer laboratories worldwide proprietary solutions with the benefit of our respective expertise and service portfolio, providing customers with access to the broadest set of solutions in the evolving market.”
1. The current alliance agreement for distribution, sales and services was extended in order to accommodate the transition phase towards the new partnership concept. The OEM agreement will be steadily implemented as the preparations in individual countries are completed.